Beyond KATHERINE: The DB-05 Shift in High-Risk HER2+ Disease

High-risk HER2-positive patients have long relied on post-neoadjuvant T-DM1, but DB-05 may change that equation.

While T-DM1 was the landmark standard, the DB-05 results show that T-DXd reduces the risk of recurrence by 53% for patients with residual disease. This clip explores why this data is redefining the post-neoadjuvant landscape, offering a more potent opportunity to prevent metastatic progression before it starts.